Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

(2016) R. Provenzano et al.   Clinical Journal of the American Society of Nephrology

The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction Study

(2016) Dorien Groenendaal-van de Meent et al.   CLINICAL THERAPEUTICS

Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity

(2016) George Hoppe et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

(2015) Anatole Besarab et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Acute kidney injury—epidemiology, outcomes and economics

(2014) Oleksa Rewa et al.   Nature Reviews Nephrology

Physiology and Pharmacology of Erythropoietin

(2014) Wolfgang Jelkmann   TRANSFUSION MEDICINE AND HEMOTHERAPY

Pan-genomic binding of hypoxia-inducible transcription factors

(2013) Johannes Schödel et al.   BIOLOGICAL CHEMISTRY

Amelioration of cisplatin-induced mouse renal lesions by a cyclooxygenase (COX)-2 selective inhibitor

(2013) Shigeyoshi Honma et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Tubular von Hippel-Lindau Knockout Protects against Rhabdomyolysis-Induced AKI

(2013) M. Fahling et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Regulation of hypoxia-inducible factor in kidney disease

(2012) Masaomi Nangaku et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Section 3: Prevention and Treatment of AKI

(2012)   Kidney International Supplements

Celecoxib, a Selective Cyclooxygenase-2 Inhibitor, Attenuates Renal Injury in a Rat Model of Cisplatin-Induced Nephrotoxicity

(2011) Ghada M. Suddek et al.   CHEMOTHERAPY

Erythropoietin (EPO) in acute kidney injury

(2011) Elizabeth Moore et al.   Annals of Intensive Care

Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis

(2010) Zhanjun Jia et al.   KIDNEY INTERNATIONAL

Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation

(2009) K. P. Kang et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Diagnosis, Epidemiology and Outcomes of Acute Kidney Injury

(2008) S. S. Waikar et al.   Clinical Journal of the American Society of Nephrology

Acute kidney injury

(2008) John A. Kellum   CRITICAL CARE MEDICINE

HIF Activation Protects From Acute Kidney Injury

(2008) A. Weidemann et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY